The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
Journal of Clinical Medicine · 14.03.2023 · 12 (6) · 2253
DOI: 10.3390/jcm12062253 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.03.2023. Verfasst von Yasunori Miyamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Miyamoto Hospital, Inashiki 300-0605, Ibaraki, Japan. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Decompensated liver cirrhosis is often complicated by refractory ascites, and intractable ascites are a predictor of poor prognosis in patients with liver cirrhosis. The treatment of ascites in patients with cirrhosis is based on the use of aldosterone blockers and loop diuretics, and occasionally vasopressin receptor antagonists are also used. Recent reports suggest that sodium–glucose cotransporter 2 (SGLT2) inhibitors may be a new treatment for refractory ascites with a different mechanism with respect to conventional agents. The main mechanisms of ascites reduction with SGLT2 inhibitors appear to be natriuresis and osmotic diuresis. However, other mechanisms, including improvements in glucose metabolism and nutritional status, hepatoprotection by ketone bodies and adiponectin, amelioration of the sympathetic nervous system, and inhibition of the renin–angiotensin–aldosterone system, may also contribute to the reduction of ascites. This literature review describes previously reported cases in which SGLT2 inhibitors were used to effectively treat ascites caused by liver cirrhosis. The discussion of the mechanisms involved is expected to contribute to establishing SGLT2 therapy for ascites in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Miyamoto Hospital, Inashiki 300-0605, Ibaraki, Japan.
- Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Ami 300-0395, Ibaraki, Japan.
- Dialysis Center, Miyamoto Hospital, Inashiki 300-0605, Ibaraki, Japan.
ORCID-Profile: Akira Honda
Zitieren
APA
Miyamoto, Y., Honda, A., Yokose, S., Nagata, M., & Miyamoto, J. (2023). The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. Journal of Clinical Medicine, 12(6), 2253. https://doi.org/10.3390/jcm12062253
Vancouver
Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. Journal of Clinical Medicine. 2023;12(6):2253. doi:10.3390/jcm12062253
BibTeX
@article{Miyamoto2023,
author = {Miyamoto, Yasunori and Honda, Akira and Yokose, Seiji and Nagata, Mariko and Miyamoto, Jiro},
title = {The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {6},
pages = {2253},
doi = {10.3390/jcm12062253}
}
EUVIMED